Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

NPS Regains Global Rights To Gattex

by Rick Mullin
March 25, 2013 | A version of this story appeared in Volume 91, Issue 12

NPS Pharmaceuticals has regained worldwide rights to recombinant human parathyroid hormone 1-84 and to Gattex, a therapy for patients with short bowel syndrome, from Japan’s Takeda Pharmaceutical. Takeda will receive NPS stock valued at $50 million and milestone payments over one year of up to $30 million. NPS had licensed rights to the compounds outside North America in 2004 and 2007, respectively, to Nycomed. Takeda acquired Nycomed in 2011.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.